

Freedom of Information Request	FOI 21-420	21 <sup>st</sup> October 2021
--------------------------------	------------	-------------------------------

**I am analysing the usage of anti-VEFG treatments for eye conditions. I would greatly appreciate if you could answer the following questions:**

- For the 4-month period from May to August 2021, how many patients has your trust treated with the following anti-VEGF treatments:**
  - **Aflibercept**
  - **Bevacizumab**
  - **Brolucizumab**
  - **Dexamethasone**
  - **Fluocinolone acetonide**
  - **Ranibizumab**

The Health Board does not record this information centrally. In order to determine this, the Health Board would have to review every patient record. Therefore, in order to comply with your request the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000, which is currently £450. As you will be aware, this is not an exemption, which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.

- For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.**
  - **Aflibercept**
  - **Bevacizumab**
  - **Brolucizumab**
  - **Dexamethasone**
  - **Fluocinolone acetonide**
  - **Ranibizumab**

Please refer to Q1.

- Within your trust, how many intra-vitreous injections/implants of each following treatments have been used (for any eye condition) in the four-month period from May to August 2021:**
  - **Aflibercept**
  - **Bevacizumab**
  - **Brolucizumab**
  - **Dexamethasone**
  - **Ranibizumab**

Type	May	June	July	August
AFLIBERCEPT (EYLEA) 3.6 mg in 0.09mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	753	887	923	905
BEVACIZUMAB 1.25 mg in 0.05mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	0	0	146	0
DEXAMETHASONE 700 micrograms Implant 1 Implant Pack	4	1	2	2
FLUOCINOLONE ACETONIDE 190 micrograms Implant 1 Implant Pack	3	0	0	0
RANIBIZUMAB 1.65 mg in 0.165mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	232	207	281	187

Note: Credits included may relate to transaction types other than those selected. Quantities are shown rounded to whole packs. Values shown are the current values of the transactions.

**4. If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from May to August 2021 for Wet Age Related Macular Degeneration (wAMD) ONLY**

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Ranibizumab

Please refer to Q1.